Understanding the Pharmacodynamics and Pharmacokinetics of MSCs to Surmount Clinical Restatement Limitations
Received Date: Oct 05, 2022 / Published Date: Oct 31, 2022
Abstract
Lately, mesenchymal stromal stem cells (MSCs) have been proposed as remedial agents because of their promising preclinical features and good safety profile. Still, their preface into clinical practice has been associated with a sour remedial profile. Beginning with substantiation of MSC bio distribution and pressing PK and PD factors, a new PK- PD model is also proposed. According to this proposition, MSCs and their released factors are crucial players in PK, and the efficacity biomarkers are considered applicable for PD in further prophetic preclinical examinations. Account for the PK- PD relationship in MSC translational exploration and proposing new models combined with better biodistribution studies could allow consummation of the pledge of further robust MSC clinical restatement.
Citation: Salvadori M (2022) Understanding the Pharmacodynamics andPharmacokinetics of MSCs to Surmount Clinical Restatement Limitations. JPharmacokinet Exp Ther 6: 152.
Copyright: © 2022 Salvadori M. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
黑料网 Journals
Article Usage
- Total views: 700
- [From(publication date): 0-2022 - Nov 23, 2024]
- Breakdown by view type
- HTML page views: 531
- PDF downloads: 169
